XML 27 R17.htm IDEA: XBRL DOCUMENT
v3.26.1

Stock-Based Compensation | 6 Months Ended
--- | ---
Jun. 30, 2026
Share-Based Payment Arrangement [Abstract] |
Stock-Based Compensation | Stock-Based Compensation 2024 Inducement Plan In January 2024, the Board of Directors ("the Board") adopted the 2024 Inducement Plan (the "Inducement Plan") without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules ("Rule 5635(c)(4)"). In accordance with Rule 5635(c)(4), the Inducement Plan allows the Company to grant awards only to a newly hired employee who was not previously an employee or non-employee director or to an employee who is being rehired following a bona fide period of non-employment if such award is a material inducement to such employee entering into employment. In January 2025, the number of shares of common stock authorized for issuance under the Inducement Plan was increased by 870,000 shares. The total number of shares of common stock authorized for issuance under the Inducement Plan as of June 30, 2026 and December 31, 2025 was 1,000,000 shares. 2020 Stock Option and Incentive Plan The total number of shares of common stock authorized for issuance under the 2020 Stock Option and Incentive Plan (the "2020 Plan”) as of June 30, 2026 and December 31, 2025 was 4,201,704 shares and 2,941,950 shares, respectively. 2017 Stock Incentive Plan The total number of shares of common stock authorized for issuance under the 2017 Stock Incentive Plan (the "2017 Plan") as of June 30, 2026 and December 31, 2025 was 395,850 shares. Any authorization to issue new options under the 2017 Plan was cancelled upon the effectiveness of the 2020 Plan and no further awards will be granted under the 2017 Plan. 2020 Employee Stock Purchase Plan The total number of shares of common stock authorized for issuance under the 2020 Employee Stock Purchase Plan (the "2020 ESPP”) as of June 30, 2026 and December 31, 2025 was 621,318 shares and 369,368 shares, respectively. Restricted Stock Units The following table summarizes the Company’s restricted stock unit activity:
| Shares |  | Weighted Average Grant Date Fair Value
Unvested as of December 31, 2025 | 501,853 |  |  | $ | 64.12 |
Issued | 171,675 |  |  | 295.02 |
Vested | (130,784) |  |  | 70.42 |
Forfeited | (19,754) |  |  | 118.59 |
Unvested as of June 30, 2026 | 522,990 |  |  | $ | 136.28 |
As of June 30, 2026, total unrecognized compensation cost related to unvested restricted stock units was $62.1 million, which is expected to be recognized over a weighted-average period of 3.16 years. Performance Stock Units In January 2026, the Company granted performance stock units ("PSUs") to its executive officers under the 2020 Plan. Vesting of the PSUs is subject to the achievement of specified performance conditions, which include achieving objectively measurable clinical, regulatory and commercial revenue targets. If these conditions are not met, the PSUs would be forfeited and returned to the plan. The actual number of common shares issued that could potentially vest is calculated by multiplying the target number of PSUs granted by a multiplier determined for each performance goal, resulting in an aggregate payout ranging from 0% to 250% of the total target PSUs granted. The performance conditions are required to be achieved during the performance period, which ends on December 31, 2027. The following table summarizes the Company’s performance stock unit activity:
| Shares |  | Grant Date Fair Value
Unvested as of December 31, 2025 | — |  |  | $ | — |
Issued(a) | 131,802 |  |  | 294.38 |
Vested | — |  |  | — |
Forfeited | — |  |  | — |
Unvested as of June 30, 2026 | 131,802 |  |  | $ | 294.38 |
(a) The number of shares issued during the period is the maximum amount of shares that could be payable under the terms of the PSU agreement. As of June 30, 2026, total unrecognized compensation costs related to unvested PSUs that were determined to be probable of achievement was $8.2 million, which is expected to be recognized over a weighted-average period of 0.54 years. Stock Options The following table summarizes the Company’s stock option activity:
| Number of Shares |  | Weighted Average Exercise Price per Share |  | Weighted Average Remaining Contractual Term |  | Aggregate Intrinsic Value
|  |  |  |  | (In years) |  | (In thousands)
Outstanding as of December 31, 2025 | 1,876,778 |  |  | $ | 89.80 |  |  |  |  |
Granted | 109,647 |  |  | 292.60 |  |  |  |  |
Exercised | (74,198) |  |  | 72.10 |  |  |  |  | $ | 18,225 |
Cancelled or Forfeited | (6,823) |  |  | 81.11 |  |  |  |  |
Outstanding as of June 30, 2026 | 1,905,404 |  |  | $ | 102.19 |  |  | 7.38 |  | $ | 466,138 |
Exercisable as of June 30, 2026 | 1,285,374 |  |  | $ | 104.01 |  |  | 6.91 |  | $ | 319,584 |
Vested and expected to vest as of June 30, 2026 | 1,905,404 |  |  | $ | 102.19 |  |  | 7.38 |  | $ | 466,138 |
Valuation of Stock Options The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees and non-employees on the date of grant were as follows for the three and six months ended June 30, 2026:
| Three Months Ended June 30, |  | Six Months Ended June 30, |  |
| 2026 |  | 2026 |  |
Risk-free interest rate | 4.26 | % |  | 3.87 | % |  |
Expected term (in years) | 6.00 |  | 6.00 |  |
Expected volatility | 78.29 | % |  | 80.09 | % |  |
Expected dividend yield | — | % |  | — | % |  |
Weighted average grant-date fair value per share | $ | 187.94 |  |  | $ | 207.72 |  |  |
As of June 30, 2026, total unrecognized compensation cost related to unvested stock options was $42.5 million, which is expected to be recognized over a weighted-average period of 2.32 years. Stock-Based Compensation Stock-based compensation expense was allocated as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2026 |  | 2025 |  | 2026 |  | 2025
Research and development | $ | 3,915 |  |  | $ | 3,230 |  |  | $ | 9,428 |  |  | $ | 7,010 |
General and administrative | 7,394 |  |  | 4,540 |  |  | 18,993 |  |  | 9,546 |
Total stock-based compensation expense | $ | 11,309 |  |  | $ | 7,770 |  |  | $ | 28,421 |  |  | $ | 16,556 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration